Personalized glucose-lowering effect of chiglitazar in type 2 diabetes.
Clinical endocrinology
Endocrinology
Human metabolism
Machine learning
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
08
07
2023
revised:
13
09
2023
accepted:
10
10
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Chiglitazar (carfloglitazar) is a peroxisome proliferator-activated receptor pan-agonist presenting non-inferior glucose-lowering efficacy with sitagliptin in patients with type 2 diabetes. To delineate the subgroup of patients with greater benefit from chiglitazar, we conducted a machine learning-based post-hoc analysis in two randomized controlled trials. We established a character phenomap based on 13 variables and estimated HbA
Identifiants
pubmed: 37942014
doi: 10.1016/j.isci.2023.108195
pii: S2589-0042(23)02272-1
pmc: PMC10628820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108195Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Diabetes Ther. 2019 Feb;10(1):149-158
pubmed: 30506494
J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9
pubmed: 16912128
J Clin Epidemiol. 2004 Mar;57(3):229-36
pubmed: 15066682
Diabetes Care. 2018 Mar;41(3):604-612
pubmed: 29279299
Expert Opin Ther Targets. 2017 Mar;21(3):333-348
pubmed: 28092722
Ann Intern Med. 2020 Jan 7;172(1):35-45
pubmed: 31711134
Arch Physiol Biochem. 2006 Jul;112(3):139-49
pubmed: 17132539
Cell Metab. 2010 Dec 1;12(6):553-4
pubmed: 21109185
Diabetes Care. 2018 Apr;41(4):705-712
pubmed: 29386249
Diabetes Care. 2022 Apr 1;45(4):965-974
pubmed: 35120199
Nat Mach Intell. 2020 Jan;2(1):56-67
pubmed: 32607472
Drug Metab Dispos. 2010 Jun;38(6):889-93
pubmed: 20190184
Diabetologia. 2022 Sep;65(9):1424-1435
pubmed: 35802168
Biol Pharm Bull. 2013;36(4):564-73
pubmed: 23546292
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Health Technol Assess. 2001;5(33):1-56
pubmed: 11701102
Sci Bull (Beijing). 2021 Aug 15;66(15):1581-1590
pubmed: 36654287
BMJ. 2018 Dec 10;363:k4245
pubmed: 30530757
Lancet Digit Health. 2022 Nov;4(11):e796-e805
pubmed: 36307193
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1678-1688
pubmed: 32518100
Diabetes. 2002 Mar;51(3):662-8
pubmed: 11872664
Diabetes. 2020 Oct;69(10):2075-2085
pubmed: 32843566
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7353-60
pubmed: 27382149
Diabetes Care. 2018 Sep;41(9):1844-1853
pubmed: 30072404
BMC Med Res Methodol. 2006 Apr 13;6:18
pubmed: 16613605
Biol Sex Differ. 2021 Jan 4;12(1):1
pubmed: 33397443
Lancet Diabetes Endocrinol. 2019 Jun;7(6):442-451
pubmed: 31047901
Sci Bull (Beijing). 2021 Aug 15;66(15):1571-1580
pubmed: 36654286
Clin Drug Investig. 2019 Jun;39(6):553-563
pubmed: 31037611
Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89
pubmed: 26405614
Lancet Diabetes Endocrinol. 2019 Jan;7(1):9-11
pubmed: 30577891
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Front Endocrinol (Lausanne). 2022 Apr 25;13:801271
pubmed: 35547000
Diabetes Care. 2020 Jul;43(7):1617-1635
pubmed: 32561617